Payment overview · 2025
General Payments
$28.43
1 reported records · 1 companies
Healthcare provider profile · identity verified
Vladimir Markovic, M.D.
Allopathic & Osteopathic Physicians|General Practice · NORFOLK, VA · NPI 1710266796
Verified facts
What the public records show
CMS Open Payments records show Vladimir Markovic, M.D. received $28.43 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.43 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $28.43 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 563 | 183 |
| Atorvastatin Calcium | Atorvastatin Calcium | 418 | 142 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 236 | 72 |
| Metformin Hcl | Metformin Hcl | 202 | 64 |
| Gabapentin | Gabapentin | 194 | 58 |
| Lisinopril | Lisinopril | 183 | 60 |
| Losartan Potassium | Losartan Potassium | 172 | 56 |
| Spironolactone | Spironolactone | 158 | 53 |
| Omeprazole | Omeprazole | 151 | 47 |
| Furosemide | Furosemide | 148 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 142 | 47 |
| Tizanidine Hcl | Tizanidine Hcl | 141 | 39 |
| Carvedilol | Carvedilol | 127 | 40 |
| Diclofenac Sodium | Diclofenac Sodium | 126 | 41 |
| Lovastatin | Lovastatin | 121 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 107 | 36 |
| Sucralfate | Sucralfate | 106 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 105 | 37 |
| Famotidine | Famotidine | 101 | 38 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 97 | 38 |
| Eliquis | Apixaban | 94 | 28 |
| Prednisone | Prednisone | 93 | 64 |
| Chlorthalidone | Chlorthalidone | 90 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 25 |
| Allopurinol | Allopurinol | 88 | 20 |
| Jardiance | Empagliflozin | 88 | 26 |
| Methocarbamol | Methocarbamol | 84 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 21 |
| Ibuprofen | Ibuprofen | 77 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 75 | 23 |
| Trazodone Hcl | Trazodone Hcl | 75 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 28 |
| Trulicity | Dulaglutide | 63 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 25 |
| Clonazepam | Clonazepam | 60 | 14 |
| Glipizide | Glipizide | 57 | 17 |
| Simvastatin | Simvastatin | 55 | 19 |
| Celecoxib | Celecoxib | 53 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 15 |
| Montelukast Sodium | Montelukast Sodium | 53 | 19 |
| Nabumetone | Nabumetone | 53 | 14 |
| Potassium Chloride | Potassium Chloride | 51 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 13 |
| Sertraline Hcl | Sertraline Hcl | 48 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 19 |
| Clonidine Hcl | Clonidine Hcl | 45 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | 11 |
| Naproxen | Naproxen | 43 | 13 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 13 |
| Ezetimibe | Ezetimibe | 38 | 13 |
| Ammonium Lactate | Ammonium Lactate | 37 | 17 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 13 |
| Meloxicam | Meloxicam | 36 | 12 |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 16 |
| Farxiga | Dapagliflozin Propanediol | 32 | 14 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | 11 |
| Baclofen | Baclofen | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Glimepiride | Glimepiride | 24 | suppressed |
| Indapamide | Indapamide | 24 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 23 | 11 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $28.43 · 1 records | ABBVIE INC. | VRAYLAR | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error